Reference:
1. Tang SX, Oliver LD, Hänsel K, DeRosse P, John M, Khairullah A, et al. Metabolic disturbances, hemoglobin A1c, and social cognition impairment in Schizophrenia spectrum disorders. Transl Psychiatry. 2022;12(1):233.
2. Toba-Oluboka T, Tibbo PG, Dempster K, Alda M. Genetic factors contribute to medication-induced QT prolongation: A review. Psychiatry Res. 2022;317:114891.
3. Rossow KM, Oshikoya KA, Aka IT, Maxwell-Horn AC, Roden DM, Van Driest SL. Evidence for Pharmacogenomic Effects on Risperidone Outcomes in Pediatrics. J Dev Behav Pediatr. 2021;42(3):205-12.
4. Rafaniello C, Sessa M, Bernardi FF, Pozzi M, Cheli S, Cattaneo D, et al. The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. Pharmacogenomics J. 2018;18(3):422-30.
5. Simon N, Torrents R, Azorin JM. Comorbidities and the right dose: antipsychotics. Expert Opin Drug Metab Toxicol. 2022;18(7-8):507-18.
6. Wichowicz H, Wilkowska A, Landowski J. Daily dose of 105 mg aripiprazole because of delusional origin: a case report. Psychiatr Danub. 2012;24(4):400-1.
7. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514-20.
8. Ferraiolo M, Ponthot R, Atik H, Koener B, Hanson J, Hermans E. Receptor density influences the recruitment bias of aripiprazole and brexpiprazole at the dopamine D(2L) receptor. Fundam Clin Pharmacol. 2022.
9. Hoosain FG, Choonara YE, Tomar LK, Kumar P, Tyagi C, du Toit LC, et al. Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy. Biomed Res Int. 2015;2015:484963.
Figure 1. Timeline of the case